JP2022554217A5 - - Google Patents
Info
- Publication number
- JP2022554217A5 JP2022554217A5 JP2022524247A JP2022524247A JP2022554217A5 JP 2022554217 A5 JP2022554217 A5 JP 2022554217A5 JP 2022524247 A JP2022524247 A JP 2022524247A JP 2022524247 A JP2022524247 A JP 2022524247A JP 2022554217 A5 JP2022554217 A5 JP 2022554217A5
- Authority
- JP
- Japan
- Prior art keywords
- ebv
- cells
- composition according
- inhibitor
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026002781A JP2026065071A (ja) | 2019-10-23 | 2026-01-09 | 養子免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903995 | 2019-10-23 | ||
| AU2019903995A AU2019903995A0 (en) | 2019-10-23 | Adoptive immunotherapy | |
| PCT/AU2020/051147 WO2021077175A1 (en) | 2019-10-23 | 2020-10-23 | Adoptive immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002781A Division JP2026065071A (ja) | 2019-10-23 | 2026-01-09 | 養子免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554217A JP2022554217A (ja) | 2022-12-28 |
| JP2022554217A5 true JP2022554217A5 (https=) | 2023-10-31 |
Family
ID=75619542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524247A Pending JP2022554217A (ja) | 2019-10-23 | 2020-10-23 | 養子免疫療法 |
| JP2026002781A Pending JP2026065071A (ja) | 2019-10-23 | 2026-01-09 | 養子免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002781A Pending JP2026065071A (ja) | 2019-10-23 | 2026-01-09 | 養子免疫療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230210984A1 (https=) |
| EP (1) | EP4048780A4 (https=) |
| JP (2) | JP2022554217A (https=) |
| KR (1) | KR20220092905A (https=) |
| CN (1) | CN114981413A (https=) |
| AU (1) | AU2020371562A1 (https=) |
| WO (1) | WO2021077175A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769474C2 (ru) * | 2017-01-20 | 2022-04-01 | Атара Байотерапьютикс, Инк. | Способы лечения рассеянного склероза с использованием аутологичных т-клеток |
| CN120789263A (zh) * | 2025-08-12 | 2025-10-17 | 中国医学科学院医学实验动物研究所 | Ulixertinib在治疗新型冠状病毒引起的肺组织炎症中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3320912B1 (en) * | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| NZ736675A (en) * | 2015-05-12 | 2023-03-31 | Memorial Sloan Kettering Cancer Center | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
| JP2019516768A (ja) * | 2016-05-25 | 2019-06-20 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞 |
| SG11201811408PA (en) * | 2016-06-24 | 2019-01-30 | Univ Mcmaster | Adoptive cell transfer and oncolytic virus combination therapy |
| EP3548049A4 (en) * | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES |
| BR112020013910A2 (pt) * | 2018-01-08 | 2020-12-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | composições e métodos para alvejamento de cânceres que expressam cd99 |
| EP3765602A1 (en) * | 2018-03-14 | 2021-01-20 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
-
2020
- 2020-10-23 AU AU2020371562A patent/AU2020371562A1/en active Pending
- 2020-10-23 CN CN202080089175.8A patent/CN114981413A/zh active Pending
- 2020-10-23 EP EP20878232.6A patent/EP4048780A4/en active Pending
- 2020-10-23 WO PCT/AU2020/051147 patent/WO2021077175A1/en not_active Ceased
- 2020-10-23 KR KR1020227017242A patent/KR20220092905A/ko active Pending
- 2020-10-23 US US17/771,375 patent/US20230210984A1/en active Pending
- 2020-10-23 JP JP2022524247A patent/JP2022554217A/ja active Pending
-
2026
- 2026-01-09 JP JP2026002781A patent/JP2026065071A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pianko et al. | Immune checkpoint blockade for hematologic malignancies: a review | |
| Economopoulou et al. | The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications | |
| Lee et al. | 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function | |
| Fend et al. | Immune checkpoint blockade, immunogenic chemotherapy or IFN-α blockade boost the local and abscopal effects of oncolytic virotherapy | |
| Hettich et al. | Checkpoint antibodies but not T cell–recruiting diabodies effectively synergize with TIL-inducing γ-irradiation | |
| Bachireddy et al. | Haematological malignancies: at the forefront of immunotherapeutic innovation | |
| Andersen | The targeting of immunosuppressive mechanisms in hematological malignancies | |
| Patel et al. | Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma | |
| Honeychurch et al. | Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell–dependent immunity to B-cell lymphoma | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| Dasari et al. | Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development | |
| Taylor et al. | Therapeutic vaccination strategies to treat nasopharyngeal carcinoma | |
| Wang et al. | Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway | |
| Tian et al. | PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses | |
| Yang et al. | Combinations of radiotherapy with immunotherapy in cervical cancer | |
| Davis et al. | Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations | |
| Nejad et al. | Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy | |
| Fan et al. | Vaccination with minigenes encoding Vh-derived major histocompatibility complex class I–binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus | |
| Patil et al. | Exploring the role of immunotherapeutic drugs in autoimmune diseases: a comprehensive review | |
| Lee et al. | Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer | |
| JP2022554217A5 (https=) | ||
| Jama et al. | Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer | |
| Barth et al. | Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma | |
| Moeini et al. | Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine |